Riociguat denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for riociguat are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Riociguat as Duplicate Therapy

BCBS issues a duplicate-therapy denial when it determines that another drug already covered under your plan provides the same or equivalent therapeutic effect as riociguat for your condition — typically pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). This is not a clinical finding by a treating physician; it is an administrative pharmacist or utilization-review determination based on therapeutic class overlap. The problem is that riociguat has a distinct mechanism of action from other pulmonary hypertension agents, and therapeutic class overlap does not mean clinical equivalence for every patient.

## Why This Denial Is Appealable

Duplicate-therapy denials are frequently overturned because they conflate therapeutic class with clinical interchangeability. Your prescriber is in a far better position than an insurance reviewer to determine whether two drugs are truly equivalent for your specific clinical situation. Under federal law: - ACA §2719 / ERISA §503 require a written internal appeal with a specific clinical rationale that addresses your individual case. - External review by an independent review organization is available after internal denial; the window is generally up to approximately four months from the denial — verify the exact deadline on your Explanation of Benefits. - Expedited review is available where delay would seriously jeopardize health.

## Your Appeal Process and Timeline

1. Request in writing the specific drug BCBS considers duplicative of riociguat and the clinical criteria used to make that determination. 2. Have your prescribing physician prepare a letter explaining the mechanistic and clinical distinctions between riociguat and the drug BCBS identified. 3. File the internal appeal with supporting documentation. Request external review if denied.

## Documentation to Gather

• Prescriber letter on clinical distinction: explains why riociguat is not therapeutically equivalent to the drug BCBS identified — different mechanism, different clinical profile, different approved uses, or documented failure/intolerance of the alternative.
• Diagnosis records: confirmation of PAH or CTEPH diagnosis and hemodynamic data from your chart establishing disease severity and subtype.
• Prior-treatment history: if you have already tried the drug BCBS calls equivalent and it failed or caused intolerance, document that specifically.
• FDA prescribing information: for riociguat, showing the approved indication(s) and mechanism distinguishing it from other classes.
• Applicable guideline reference: your prescriber may reference the relevant ACC/AHA or ERS/ESC pulmonary hypertension guideline organization's guidance on combination or sequential therapy.

## Criteria-Mapping Structure

List each basis BCBS used to call riociguat a duplicate, and in a parallel column provide the specific clinical or mechanistic fact that rebuts it. The goal is to show that the drugs are not interchangeable for your patient profile, not just that they are in different classes.